{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:34:34Z","timestamp":1783517674442,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":160,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100589","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T17:33:04Z","timestamp":1655055184000},"page":"100589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials"],"prefix":"10.1016","volume":"32","author":[{"given":"Farida","family":"Nazeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-8699","authenticated-orcid":false,"given":"Jissy V.","family":"Poulose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-3074","authenticated-orcid":false,"given":"Cessal Thommachan","family":"Kainickal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctarc.2022.100589_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/ijc.10894","article-title":"Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality","volume":"103","author":"Lee","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2022.100589_bib0002","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100589_bib0003","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ijc.2910150414","article-title":"An additional younger-age peak for cancer of the nasopharynx","volume":"15","author":"Balakrishnan","year":"1975","journal-title":"Int. J. Cancer"},{"issue":"9084","key":"10.1016\/j.ctarc.2022.100589_bib0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(97)07269-3","article-title":"Nasopharyngeal carcinoma","volume":"350","author":"Vokes","year":"1997","journal-title":"The Lancet."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100589_bib0005","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.ctarc.2022.100589_bib0006","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ctarc.2022.100589_bib0007","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","article-title":"Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group","volume":"23","author":"Lee","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2006.03.054","article-title":"Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and\/or accelerated fractionation for locally advanced nasopharyngeal carcinoma","volume":"66","author":"Lee","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"22","key":"10.1016\/j.ctarc.2022.100589_bib0009","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/JCO.2004.10.074","article-title":"The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature","volume":"22","author":"Langendijk","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100589_bib0011","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100589_bib0012","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What Is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100589_bib0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2022.100589_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"Chen","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100589_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13566-012-0032-0","article-title":"If concurrent\u2013adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction\u2013concurrent achieve better outcome?","volume":"1","author":"Lee","year":"2012","journal-title":"J. Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100589_bib0016","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JOP.18.00219","article-title":"Management of nasopharyngeal carcinoma: is adjuvant therapy needed?","volume":"14","author":"Lee","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2017.07.020","article-title":"Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial","volume":"126","author":"Yang","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"3, Supplement","key":"10.1016\/j.ctarc.2022.100589_bib0018","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.ijrobp.2021.07.320","article-title":"Five-year result after reduction of the target volume of intensity modulated radiotherapy following induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial","volume":"111","author":"Xiang","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"issue":"12","key":"10.1016\/j.ctarc.2022.100589_bib0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100589_bib0021","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: A randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma","volume":"91","author":"Tan","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100589_bib0022","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin- 5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100589_bib0023","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","volume":"29","author":"Hong","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100589_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2022.100589_bib0025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100589_bib0027","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"30","key":"10.1016\/j.ctarc.2022.100589_bib0028","doi-asserted-by":"crossref","first-page":"48375","DOI":"10.18632\/oncotarget.10237","article-title":"Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0029","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2018.02.027","article-title":"Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis","volume":"129","author":"Tan","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0030","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1002\/ONCO.13520","article-title":"Meta-analysis on induction chemotherapy in locally advanced nasopharyngeal carcinoma","volume":"26","author":"Man\u00e9","year":"2021","journal-title":"Oncologist"},{"issue":"91","key":"10.1016\/j.ctarc.2022.100589_bib0031","article-title":"The most efficacious induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: a network meta-analysis","volume":"11","author":"Choi","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100589_bib0032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tranon.2019.01.002","article-title":"Cisplatin and fluorouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyngeal carcinoma","volume":"12","author":"Jin","year":"2019","journal-title":"Transl. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100589_bib0033","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00432-020-03229-3","article-title":"Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China","volume":"146","author":"Zang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2022.100589_bib0034","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1002\/cncr.32972","article-title":"NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2020","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100589_bib0035","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1200\/JCO.2021.39.15_suppl.6065","article-title":"Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma","volume":"39","author":"Xu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100589_bib0036","article-title":"Effect of Induction Chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","author":"Li","year":"2022","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100589_bib0037","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100589_bib0038","unstructured":"TPF+CCRT vs. CCRT+PF in High-Risk Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03306121."},{"key":"10.1016\/j.ctarc.2022.100589_bib0039","unstructured":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574324."},{"key":"10.1016\/j.ctarc.2022.100589_bib0040","unstructured":"Induction Versus Adjuvant Gemcitabine\/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04898374."},{"key":"10.1016\/j.ctarc.2022.100589_bib0041","unstructured":"ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05062005."},{"key":"10.1016\/j.ctarc.2022.100589_bib0042","unstructured":"Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00997906."},{"key":"10.1016\/j.ctarc.2022.100589_bib0043","unstructured":"Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437329."},{"key":"10.1016\/j.ctarc.2022.100589_bib0044","unstructured":"GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840421."},{"key":"10.1016\/j.ctarc.2022.100589_bib0045","unstructured":"Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03919552."},{"key":"10.1016\/j.ctarc.2022.100589_bib0046","unstructured":"Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03366415."},{"key":"10.1016\/j.ctarc.2022.100589_bib0047","unstructured":"Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02434614."},{"key":"10.1016\/j.ctarc.2022.100589_bib0048","unstructured":"Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03015727."},{"key":"10.1016\/j.ctarc.2022.100589_bib0049","unstructured":"Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384627."},{"key":"10.1016\/j.ctarc.2022.100589_bib0050","unstructured":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04456322."},{"key":"10.1016\/j.ctarc.2022.100589_bib0051","unstructured":"Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04453826."},{"key":"10.1016\/j.ctarc.2022.100589_bib0052","unstructured":"Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03700476."},{"key":"10.1016\/j.ctarc.2022.100589_bib0053","unstructured":"Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04448522."},{"key":"10.1016\/j.ctarc.2022.100589_bib0054","unstructured":"The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02460887."},{"key":"10.1016\/j.ctarc.2022.100589_bib0055","unstructured":"Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03908372."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100589_bib0056","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/path.5249","article-title":"Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker","volume":"247","author":"Lam","year":"2019","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100589_bib0057","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100589_bib0058","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1186\/s12885-021-08408-0","article-title":"Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"issue":"31","key":"10.1016\/j.ctarc.2022.100589_bib0059","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma Epstein-Barr Virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","volume":"36","author":"Chan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100589_bib0060","series-title":"Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma","first-page":"270","author":"Ma","year":"2020"},{"issue":"10192","key":"10.1016\/j.ctarc.2022.100589_bib0061","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2022.100589_bib0062","unstructured":"Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02135042."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100589_bib0063","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1200\/JCO.2021.39.15_suppl.6005","article-title":"Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial","volume":"39","author":"Miao","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100589_bib0064","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1200\/JCO.2021.39.15_suppl.6003","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial","volume":"39","author":"Ma","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422200079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:11Z","timestamp":1762842911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422200079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":64,"alternative-id":["S246829422200079X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100589","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100589"}}